When a patient gets an alert, their top priority is to resolve it by making a treatment decision or fixing a system issue. Afterwards, they can acknowledge the alert on their display device by tapping OK. Until they acknowledge the alert, it will sound every 5 minutes. 

Dexcom G7 has new alert sounds and sound options. 

The new Quiet Mode allows users to override phone settings: 

• Quiet Mode (Vibrate): When this setting is enabled, all Dexcom G7 CGM System alerts will vibrate. Urgent Low Soon and technical alerts will still escalate to sound if not acknowledged. 

• Vibrate: All alerts vibrate but won’t sound. Users can set vibrate mode for up to 6 hours or indefinitely. Smartphone vibrate setting must be on for the alerts to vibrate. 

The Dexcom G7 Alert Profile replaces the Alert Schedule from Dexcom G6. The Alert Profile allows users to customize a second group of alerts, which can be used in two ways: 

• Switch between them manually 

• Set up a schedule to switch between alerts automatically; for example, to set different alert schedules for daytime and nighttime. 

The latest Apple iPhones and many of the popular Android smart phones are compatible with both Dexcom G6 and G7; however, there are some differences between the systems. Some of the newest Android phones are still being tested and will be added as they pass our testing.  Some of the older Android phones will not be added for Dexcom G7 as we prioritize adding new phones as quickly as possible.  

Dexcom G7 is compatible with the latest Apple iPhones and many popular Android devices. We are regularly adding more devices, so your patients can stay informed by visiting dexcom.com/compatibility.  

For patients whose smart device is not currently compatible with Dexcom G7, we encourage users to take advantage of the newly redesigned G7 receiver that is smaller, with a more vibrant, easier to read display. 

Because the G6 and G7 smart phone apps work independently of each other, it is possible to wear both G6 and G7 at the same time. However, if a patient wears two CGM sensors at the same time the numbers might be different because they are sensing local tissue glucose levels in separate locations on the body. Dexcom recommends using either Dexcom G6 or Dexcom G7, but not both simultaneously. 

Yes, G6 will still be available to patients once G7 launches. Some patients should continue using G6 while G7 insurance coverage is expanded, and connectivity with connected insulin pumps is rolled out. 

• #1 in Accuracy¹: Dexcom G7 has an overall MARD of 8.1% for pediatrics and 8.2% for adults as published in our U.S. pivotal trial data. FreeStyle Libre 3 (L3) is FDA cleared with an overall accuracy of 8.9% for adults and 9.4% for pediatrics as listed in their U.S. User Guide^##. 

• Less Downtime^**: G7 warms up in just 30 minutes after which you can immediately make insulin dosing decisions.  L3 requires 12 hours before dosing decisions^##, which would make it unable to work with a connected system in the future. Dexcom CGM Systems adherence and persistence is nearly 30% higher with Dexcom over Libre.13 

• More Reliable: G7 has an automatic predictive low alert to help prevent a low, while L3’s threshold alerts only notify you the minute after you went low^##. 

• Medicare Support: RT-CGM is recommended for older adults, per ADA¹¹ and AACE¹² guidelines, and G6 and G7 both fulfill Medicare requirements.  L3, Abbott’s only RT-CGM, does not fulfill Medicare requirements due to the lack of a dedicated receiver. 

• Most Proven Outcomes: Dexcom generates the most amount of clinical data and has been evaluated in a greater number of studies¹ – over 300 clinical trials – on the value and benefit of CGM across the spectrum of diabetes states and methodologies to remain focused on measuring and driving the best outcomes. 

• Proven Connectivity Platform: Dexcom G7 is already part of Dexcom’s industry leading connected CGM ecosystem¹ to allow patients to manage their diabetes with the insulin and lifestyle hardware and software that works best for them.  With 4 years of proven connectivity and a saleable real-time API, Dexcom is the only CGM brand to offer AID and have a larger connectivity platform. L3 explicitly has an AID contraindication.^## 

• Overall Patient Experience: Dexcom is the #1 most recommended CGM brand by both patients and HCPs 6, #1 in patient retention7, and #1 in patient satisfaction^§§. Libre users switch to Dexcom 3x more frequently than Dexcom users switch to Libre⁸. 
  
  
  
   

  *Smart device, sold separately, required to display readings on watch. †Compatible smart devices sold separately. For a list of compatible devices, visit dexcom.com/compatibility. ||Results obtained with a prior generation Dexcom CGM System. ¶Separate Follow app and internet connection required. Users should always confirm readings on the Dexcom G6 app or receiver before making treatment decisions. #Compared to a prior generation Dexcom CGM System. **Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. ††Healthcare providers can register for Dexcom Clarity at clarity.dexcom.com/professional/ registration. ‡‡An internet connection is required for patients to send their glucose data to Dexcom Clarity via a compatible smart device: dexcom.com/compatibility. Healthcare providers will only be able to view a patient’s glucose data if the patient elects to share it with them through Dexcom Clarity. §§Comparison of NPS scores of Dexcom, Abbott, and Medtronic, Seagrove Survey 2021 Patient Perspectives. ##Libre 3 user guide 

  1 Dexcom, data on file, 2022. 2 Beck, RW, et al. JAMA. 2017;317(4):371-378. 3 Welsh JB, et al. J Diabetes Sci Technol. Jun 13 2022:19322968221099879. 4 Dexcom G7 CGM System User Guide. 2022. 5 Managed Markets Insights & Technology, LLC. MMIT Analytics, June 2022. 6 dQ&A US Q1 2021 Diabetes Connections Patient Panel Report. 2021;69-72.  7 IQVIA, February 2022. 8 Data on File. IQVIA 2022 9 Dexcom G7 User Guide. 10 GoodRx Program: Set buy down per finance of $200 for sensors and transmitters 11 American Diabetes Association. Standards of Medical Care in Diabetes - 2023. Diabetes Care. 2023;45(S1):S1-291. 12 Grunberger G, et al. Endocr Pract. 2021;27(6):505-537. 13 IQVIA, February 2022 - According to IQVIA, patient retention data is the sum of persistent and reinitiated patients. Persistent patients are the patients who remain on therapy without interruption (days’ supply + 30-day grace period). Reinitiated patients are the group that has interruption in use. These data are for new IIT patients across all channels from September 2020 to August 2021. 

No. Dexcom G6 sensors, transmitters, and receivers are not compatible with the Dexcom G7 CGM app, sensors, nor receivers. If a compatible smart device is needed for the Dexcom G7 sensor, a patient must download the new Dexcom G7 app. The Dexcom G7 CGM system works with the existing Clarity and Follow apps.

Dexcom is working closely with its insulin pump partners to integrate Dexcom G7 into current and future automated insulin delivery systems as quickly as possible. 

Calibration is not required but conducting optional blood glucose (BG) calibrations can move your patient’s sensor reading closer to their BG meter value. 

The new Dexcom G7 CGM System requires sensors and a compatible display device. If your patient uses a compatible smart device, they will need to download the new Dexcom G7 app. An optional receiver is available as well.